Magnesium-deficient diet alters depression- and anxiety-related behavior in mice - Influence of desipramine and Hypericum perforatum extract

Neuropharmacology

Volumn 47, Issue 8, 2004, Pages 1189-1197

  Singewald, Nicolas ^a   Sinner, Catrin ^a   Hetzenauer, Alfred ^a   Sartori, Simone B ^a   Murck, Harald ^b  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b Lichtwer Pharma AG   (Germany)

Author keywords

Animal model; Antidepressant; Anxiety; Anxiolytic; Depression; Magnesium depletion

Indexed keywords

DESIPRAMINE; HYPERICUM PERFORATUM EXTRACT; MAGNESIUM;

ANIMAL BEHAVIOR; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DEPRESSION; DIETARY INTAKE; DRUG SCREENING; DRUG SENSITIVITY; FORCED SWIMMING TEST; HYPERICUM PERFORATUM; IMMOBILIZATION; LIGHT DARK CYCLE; LOCOMOTION; MAGNESIUM DEFICIENCY; MOTOR COORDINATION; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; TASK PERFORMANCE; VALIDATION PROCESS;

ANIMALS; ANXIETY; DEPRESSION; DESIPRAMINE; HYPERICUM; LOCOMOTION; MAGNESIUM DEFICIENCY; MICE; MICE, INBRED C57BL; PLANT EXTRACTS;

EID: 9644288037     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2004.08.010     Document Type: Article

References (56)

1. Banki C.M., Vojnik M., Papp Z., Balla K.Z., Arato M. Cerebrospinal fluid magnesium and calcium related to amine metabolites, diagnosis, and suicide attempts. Biological Psychiatry. 20:1985;163-171
2. Blanchard D.C., Sakai R.R., McEwen B., Weiss S.M., Blanchard R.J. Subordination stress: behavioral, brain, and neuroendocrine correlates. Behavioral Brain Research. 58:1993;113-121
3. Borsini F., Podhorna J., Marazziti D. Do animal models of anxiety predict anxiolytic-like effects of antidepressants? Psychopharmacology (Berlin). 163:2002;121-141
4. Buchmeiser M.R., Seeber G., Tessadri R. Quantification of lanthanides in rocks using succinic acid-derivatized sorbents for on-line SPE-RP-ion-pair HPLC. Analytical Chemistry. 72:2000;2595-2602
5. Butterweck V., Korte B., Winterhoff H. Pharmacological and endocrine effects of Hypericum perforatum and hypericin after repeated treatment. Pharmacopsychiatry. 34:(Suppl. 1):2001;S2-S7
6. Caldarone B.J., Karthigeyan K., Harrist A., Hunsberger J.G., Wittmack E., King S.L., Jatlow P., Picciotto M.R. Sex differences in response to oral amitriptyline in three animal models of depression in C57BL/6J mice. Psychopharmacology (Berlin). 170:2003;94-101
7. Cervo L., Rozio M., Ekalle-Soppo C.B., Guiso G., Morazzoni P., Caccia S. Role of hyperforin in the antidepressant-like activity of Hypericum perforatum extracts. Psychopharmacology (Berlin). 164:2002;423-428
8. Chouinard G., Beauclair L., Geiser R., Etienne P. A pilot study of magnesium aspartate hydrochloride (Magnesiocard) as a mood stabilizer for rapid cycling bipolar affective disorder patients. Progress in Neuro- Psychopharmacology and Biological Psychiatry. 14:1990;171-180
9. Cole J.C., Rodgers R.J. Ethological comparison of the effects of diazepam and acute/chronic imipramine on the behaviour of mice in the elevated plus-maze. Pharmacology, Biochemistry, and Behavior. 52:1995;473-478
10. Cox I.M., Campbell M.J., Dowson D. Red blood cell magnesium and chronic fatigue syndrome. Lancet. 337:1991;757-760
11. Crawley J.N. Neuropharmacologic specificity of a simple animal model for the behavioral actions of benzodiazepines. Pharmacology, Biochemistry, and Behavior. 15:1981;695-699
12. Cryan J.F., Markou A., Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends in Pharmacological Science. 23:2002;238-245
13. D'Sa C., Duman R.S. Antidepressants and neuroplasticity. Bipolar Disorders. 4:2002;183-194
14. Decollogne S., Tomas A., Lecerf C., Adamowicz E., Seman M. NMDA receptor complex blockade by oral administration of magnesium: comparison with MK-801. Pharmacology, Biochemistry, and Behavior. 58:1997;261-268
15. Ebner K., Rupniak N.M., Saria A., Singewald N. Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats. Proceedings of the National Academy of Science USA. 101:2004;4280-4285
16. Facchinetti F., Borella P., Sances G., Fioroni L., Nappi R.E., Genazzani A.R. Oral magnesium successfully relieves premenstrual mood changes. Obstetrics and Gynecology. 78:1991;177-181
17. Fernandez-Guasti A., Martinez-Mota L., Estrada-Camarena E., Contreras C.M., Lopez-Rubalcava C. Chronic treatment with desipramine induces an estrous cycle-dependent anxiolytic-like action in the burying behavior, but not in the elevated plus-maze test. Pharmacology, Biochemistry, and Behavior. 63:1999;13-20
18. Flausino O.A. Jr., Zangrossi H. Jr., Salgado J.V., Viana M.B. Effects of acute and chronic treatment with Hypericum perforatum L. (LI 160) on different anxiety-related responses in rats. Pharmacology, Biochemistry, and Behavior. 71:2002;251-257
19. Franklin M., Reed A., Murck H. Sub-chronic treatment with an extract of Hypericum perforatum (St John's wort) significantly reduces cortisol and corticosterone in the rat brain. European Neuropsychopharmacology. 14:2004;7-10
20. Garcy A.M., Marotta S.F. Effects of cerebroventricular perfusion with monovalent and divalent cations on plasma cortisol of conscious cats. Neuroendocrinology. 26:1978;32-40
21. Goodwin G.M., Green A.R., Johnson P. 5-HT2 receptor characteristics in frontal cortex and 5-HT2 receptor-mediated head-twitch behaviour following antidepressant treatment to mice. British Journal of Pharmacology. 83:1984;235-242
22. Greeson J.M., Sanford B., Monti D.A. St. John's wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology (Berlin). 153:2001;402-414
23. Grimaldi B.L. The central role of magnesium deficiency in Tourette's syndrome: causal relationships between magnesium deficiency, altered biochemical pathways and symptoms relating to Tourette's syndrome and several reported comorbid conditions. Medical Hypotheses. 58:2002;47-60
24. Grunze H., Walden J. Reduction of the frequency of occurrence of low magnesium induced field potentials in the hippocampus slice preparation of guinea pigs: a good screening tool for calcium antagonistic effects of anticonvulsant and antipsychotic drugs. Magnesium Research. 10:1997;119-126
25. Held K., Antonijevic I.A., Kunzel H., Uhr M., Wetter T.C., Golly I.C., Steiger A., Murck H. Oral Mg(2+) supplementation reverses age-related neuroendocrine and sleep EEG changes in humans. Pharmacopsychiatry. 35:2002;135-143
26. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology. 23:2000;477-501
27. Kaehler S.T., Sinner C., Chatterjee S.S., Philippu A. Hyperforin enhances the extracellular concentrations of catecholamines, serotonin and glutamate in the rat locus coeruleus. Neuroscience Letters. 262:1999;199-202
28. Kantak K.M. Magnesium deficiency alters aggressive behavior and catecholamine function. Behavioral Neuroscience. 102:1988;304-311
29. Karolewicz B., Paul I.A. Group housing of mice increases immobility and antidepressant sensitivity in the forced swim and tail suspension test. European Journal of Pharmacology. 415:2001;197-201
30. Kumar V., Singh P.N., Bhattacharya S.K. Anti-stress activity of Indian Hypericum perforatum L. Indian Journal of Experimental Biology. 39:2001;344-349
31. Langosch J.M., Zhou X.Y., Heinen M., Kupferschmid S., Chatterjee S.S., Noldner M., Walden J. St John's wort (Hypericum perforatum) modulates evoked potentials in guinea pig hippocampal slices via AMPA and GABA receptors. European Neuropsychopharmacology. 12:2002;209-216
32. Leonard B.E. Noradrenaline in basic models of depression. European Neuropsychopharmacology. 7:(Suppl. 1):1997;S11-S16. Discussion, S71-S73
33. Levine J., Stein D., Rapoport A., Kurtzman L. High serum and cerebrospinal fluid Ca/Mg ratio in recently hospitalized acutely depressed patients. Neuropsychobiology. 39:1999;63-70
34. Mayer M.L., Westbrook G.L., Guthrie P.B. Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones. Nature. 309:1984;261-263
35. Mennini T., Gobbi M. The antidepressant mechanism of Hypericum perforatum. Life Sciences. 75:2004;1021-1027
36. Murck H. Magnesium and affective disorders. Nutritional Neuroscience. 5:2002;375-389
37. Murck H. Atypical depression spectrum disorder - neurobiology and treatment. Acta Neuropsychiatrica. 15:2003;227-241
38. Murck H., Steiger A. Mg2+ reduces ACTH secretion and enhances spindle power without changing delta power during sleep in men - possible therapeutic implications. Psychopharmacology (Berlin). 137:1998;247-252
39. Nemeroff C.B., Owens M.J. Treatment of mood disorders. Nature Neuroscience. 5:(Suppl.):2002;1068-1070
40. Parker G. 'New' and 'old' antidepressants: all equal in the eyes of the lore? British Journal of Psychiatry. 179:2001;95-96
41. Paul I.A., Nowak G., Layer R.T., Popik P., Skolnick P. Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. Journal of Pharmacology and Experimental Therapeutics. 269:1994;95-102
42. Poleszak, E., Szewczyk, B., Kȩdzierska, E., Wlaź, P., Pilc, A., Nowak, G., 2004. Antidepressant- and anxiolytic-like activity of magnesium in mice. Pharmacology, Biochemistry, and Behavior 78, 7-12.
43. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Archives Internationales de Pharmacodynamie et de Therapie. 229:1977;327-336
44. Rasmussen H.H., Mortensen P.B., Jensen I.W. Depression and magnesium deficiency. International Journal of Psychiatry in Medicine. 19:1989;57-63
45. Rommelspacher H., Siemanowitz B., Mannel M. Acute and chronic actions of a dry methanolic extract of Hypericum perforatum and a hyperforin-rich extract on dopaminergic and serotonergic neurones in rat nucleus accumbens. Pharmacopsychiatry. 34:(Suppl. 1):2001;S119-S126
46. Seelig M.S. Consequences of magnesium deficiency on the enhancement of stress reactions; preventive and therapeutic implications (a review). Journal of the American College of Nutrition. 13:1994;429-446
47. Shiekhattar R., Aston-Jones G. NMDA-receptor-mediated sensory responses of brain noradrenergic neurons are suppressed by in vivo concentrations of extracellular magnesium. Synapse. 10:1992;103-109
48. Sinnegger-Brauns, M.J., Hetzenauer, A., Huber, I.G., Renström, E., Wietzorrek, G., Berjukov, S., Cavalli, M., Walter, D., Waldschütz, R., Hering, S., Bova, S., Rorsman, P., Pongs, O., Singewald, N., Striessnig, J., 2004. Cav1.3 L-type Ca2+-channels: role for isoform-specific regulation of mood behavior, pancreatic β-cell and cardiovascular function. Journal of Clinical Investigation 113, 1430-1439.
49. Stewart C.A., Reid I.C. Antidepressant mechanisms: functional and molecular correlates of excitatory amino acid neurotransmission. Molecular Psychiatry. 7:(Suppl. 1):2002;S15-S22
50. Topf J.M., Murray P.T. Hypomagnesemia and hypermagnesemia. Reviews in Endocrine and Metabolic Disorders. 4:2003;195-206
51. Trullas R., Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. European Journal of Pharmacology. 185:1990;1-10
52. Tschenett A., Singewald N., Carli M., Balducci C., Salchner P., Vezzani A., Herzog H., Sperk G. Reduced anxiety and improved stress coping ability in mice lacking NPY-Y2 receptors. European Journal of Neuroscience. 18:2003;143-148
53. Vandenbogaerde A., Zanoli P., Puia G., Truzzi C., Kamuhabwa A., De Witte P., Merlevede W., Baraldi M. Evidence that total extract of Hypericum perforatum affects exploratory behavior and exerts anxiolytic effects in rats. Pharmacology, Biochemistry, and Behavior. 65:2000;627-633
54. Watanabe Y., Saito H., Abe K. Tricyclic antidepressants block NMDA receptor-mediated synaptic responses and induction of long-term potentiation in rat hippocampal slices. Neuropharmacology. 32:1993;479-486
55. Wonnemann M., Singer A., Muller W.E. Inhibition of synaptosomal uptake of 3H-L-glutamate and 3H-GABA by hyperforin, a major constituent of St. John's wort: the role of amiloride sensitive sodium conductive pathways. Neuropsychopharmacology. 23:2000;188-197
56. Zimmerman M., Chelminski I., McDermut W. Major depressive disorder and axis I diagnostic comorbidity. Journal of Clinical Psychiatry. 63:2002;187-193